[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hcv-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hcv-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,82,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100624695","pregnancy-and-viral-infections-impact-on-pregnant-women-and-their-children-french-prospective-cohort-100624695",false,"NCT07412977","\"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort\"","\"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort.\"","VIROPREG","Inclusion Criteria:\n\nPregnant women :\n\n* Cis-gender pregnant woman wishing to carry her pregnancy to term and give birth in one of the maternity units participating in the research, whatever the term of pregnancy (inclusion as soon as possible after conception, whatever the outcome);\n* Age ≥18 years;\n* Viral infection studied known before pregnancy or diagnosed during pregnancy;\n* Signed, free, informed and written consent;\n* Be cared for in one of the maternity units taking part in the study\n\nNewborns\u002Fchildren:\n\n\\- Free, informed, written and signed consent of parental guardians.\n\nExclusion Criteria:\n\nPregnant women :\n\n* Planned delivery in a non-study center;\n* Planned absence that could hinder participation in the research;\n* Vulnerable population (minors, persons under guardianship or trusteeship, or persons deprived of their liberty by judicial or administrative decision);\n* Level of French oral comprehension insufficient according to the investigator for the research process understanding\n\nNewborns\u002Fchildren:\n\n* Refusal of parental authority to allow newborn\u002Fchild to participate in study\n* Follow-up of the child planned in a center not participating in the study\n* Scheduled absence of parents that could hinder the child's participation in the study;","FEMALE","18 Years",{"count":20,"type":21},5160,"ESTIMATED","OBSERVATIONAL","The VIROPREG study is a French prospective multicenter cohort study that aims to assess the impact of viral infections and antiviral treatments received during pregnancy on maternal and child health. The study focuses on both chronic viral infections: human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)\\] and on arbovirus infections.\n\nThis study aims at investigating the following research questions:\n\n* What is the rate of mother-to-child transmission for each virus?\n* What are the effects of maternal infection on (i) pregnancy outcomes, (ii) the mother's physical and psychological health, and (iii) the fetus' health and development, with a focus on long-term psychomotor development in children born to women living with HIV?\n* What is the impact of antiretroviral and\u002For antiviral prophylactic and\u002For therapeutic treatments administered during pregnancy on maternal and fetal health? Mother-child pairs will be followed from pregnancy through delivery and from birth until the child reaches 7 years of age. Each mother-child pair will be enrolled into one of four cohort groups based on the maternal infection.\n\nHIV Cohort:\n\nPregnant women living with HIV who participate in the research will:\n\n* Be followed according to the routine care schedule from enrollment to post-natal visit usually scheduled in maternity after delivery (6-8 weeks post-partum)\n* Participate in additional follow-up by phone call or videoconference at 4- and 7-years post-partum for research purposes\n* Complete questionnaires at inclusion, delivery, 4- and 7- years postpartum\n* In case of breastfeeding, receive follow-up care aligned with routine schedules for up to 2 years postpartum, including 2 additional visits specifically for research at 2- and 3- months postpartum.\n* In selected cases: provide blood, umbilical cord blood, colostrum and breast milk samples during follow-up visits for research purposes (pharmacological and virological analyses).\n\nChildren born to mothers living with HIV and who participate in the research will:\n\n* Be followed according to the routine care schedule from birth until 2 years of age\n* Participate in additional follow-up by phone call or videoconference, addressed to mothers, at 4- and 7- years of age for research purposes.\n\nHBV Cohort:\n\nPregnant HBV-infected women who participate in the research will:\n\n* Be followed according to the routine care schedule from enrollment to post-natal visit usually scheduled in maternity after delivery (6- 8 weeks post-partum)\n* Complete questionnaires at inclusion and delivery\n* Provide blood samples during follow-up visits for research purposes.\n\nChildren born to HBV-infected mothers and who participate in the research will:\n\n* Be followed according to the routine care schedule from birth to 2 years of age\n* Participate in additional follow-up for research purposes at 3 months and 18-24 months of age.\n\nHCV Cohort:\n\nPregnant HCV-infected women who participate in the research will:\n\n* Be followed according to the routine care schedule from enrollment to post-natal visit usually scheduled in maternity after delivery (6 - 8 weeks post-partum)\n* Complete questionnaires at inclusion and delivery\n* Provide blood samples during follow-up visits for research purposes.\n\nChildren born to HCV-infected mothers and who participate in the research will:\n\n* Be followed according to the routine care schedule from birth until 2 years of age\n* Attend additional follow-up visits scheduled at 3 and 9 months of age for research purposes.\n\nArbovirus Cohort:\n\nPregnant women infected with arbovirus who participate in the research will:\n\n* Be followed according to the routine care schedule from enrollment to delivery\n* Participate in additional follow-up for research purposes at 4 years after delivery.\n* In case of breastfeeding, women will be monitored for research purposes at Day 7 and Day 30 postpartum\n* Complete questionnaires at inclusion, Day 7-10 from the inclusion, delivery and 4 years after delivery\n* Provide blood, amniotic fluid, placenta, umbilical cord blood, colostrum and breast milk samples during follow-up visits for research purposes.\n\nChildren born to mothers infected with arbovirus and who participate in the research will:\n\n* Be followed according to the routine care schedule from birth until 2 years of age.\n* Participate in additional follow-up for research purposes at inclusion, Day 7 and Day 30 after inclusion\n* Participate in additional follow-up by phone call or videoconference, addressed to mothers, at 4- and 7- years of age for research purposes.",[25,26,27,28,29],"HIV Infection","HBV Infection","HDV Infection","HCV Infection","Arbovirus Infections",[31,32,33,34,35,36,37,38,39,40,41,42],"Pregnancy","HIV","HBV","HCV","Arbovirus","National health data system","Neurocognitive disorders","Quality of life","Pregnancy viral infections","Mother-to-child transmission","Social epidemiology","Hepatitis","NOT_YET_RECRUITING","2026-02-09",{"date":46,"type":47},"2026-02-17","ACTUAL",{"date":49,"type":21},"2026-02",{"date":51,"type":21},"2039-12",{"name":53,"class":54},"ANRS, Emerging Infectious Diseases","OTHER_GOV",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":18,"maxAge":65,"enrollmentInfo":66,"targetDuration":68,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100611544","hepatitis-b-and-c-within-the-chinese-community-in-milan-100611544","NCT07241962","Hepatitis B and C Within the Chinese Community in Milan","Prevalence of Hepatitis B and C Within the Chinese Community Residing in Milan","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Self-identified as part of the Chinese community residing in Milan\n* Willing and able to provide informed consent\n* Willing to undergo HBV and\u002For HCV rapid screening (capillary blood test)\n* Able to complete an anonymous questionnaire on demographics, risk factors and awareness of HBV and HCV infections\n* Able to communicate in Italian or Chinese (with interpreter assistance, if needed)\n\nExclusion Criteria:\n\n* Age under 18 or over 50 years\n* Not from the Chinese community or not residing in Milan\n* Unable to provide informed consent\n* Currently undergoing treatment for HBV or HCV, or with previously confirmed diagnosis of HBV or HCV\n* Severe mental or physical illness impairing participation or understanding of consent\n* Unable to respond to the questionnaire, even with interpreter assistance\n* Pregnant women",true,"ALL","50 Years",{"count":67,"type":21},1000,"1 Day","The goal of this observational study is to assess the effectiveness of targeted screening for Hepatitis B (HBV) and Hepatitis C (HCV) infections in adults aged 18 to 50 from the Chinese community residing in Milan.\n\nThe main questions it aims to answer are:\n\n* Does community-based, culturally sensitive screening increase the detection of undiagnosed HBV and HCV infections in this high-risk population?\n* What is the level of adherence, satisfaction and awareness regarding rapid testing methods in this community?\n\nParticipants will:\n\n* Receive pre-test counseling in Italian or Chinese with the help of an interpreter\n* Complete a brief, anonymous questionnaire on demographics, risk factors and awareness of HBV\u002FHCV\n* Undergo capillary rapid testing for HBV and\u002For HCV\n* Receive test results during the same visit\n* Complete a short post-test satisfaction questionnaire\n\nThe study will be conducted in public spaces within Milan's Chinatown, during monthly sessions, until 1,000 participants are enrolled. Each session will last approximately 30-60 minutes per participant.",[71,28],"HBV (Hepatitis B Virus)","2025-11-17",{"date":74,"type":47},"2025-11-21",{"date":76,"type":21},"2025-12",{"date":78,"type":21},"2026-12",{"name":80,"class":81},"IRCCS Ospedale San Raffaele","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100589255","the-epidemic-status-and-development-trend-of-hepatitis-c-virus-infection-in-pregnant-women-in-xian-100589255","NCT06952036","The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an","The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an: A 10-Year Retrospective Study","Inclusion Criteria:\n\n1. Pregnant women or parturient women confirmed by blood HCG test.\n2. Patients aged 18 years old and above.\n3. Patients with HCV antibody seropositive or HCV RNA positive from 2014-2023.\n\nExclusion Criteria:\n\n1. Patients without valid telephone numbers.\n2. Duplicate records: For duplicate records of the same pregnant woman, only one record should be kept.",{"count":90,"type":21},200000,"The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women.\n\nTo understand the epidemiological changes and status of hepatitis C virus (HCV) infection in pregnant women in Shaanxi province in recent 10 years, and to analyze the main influencing factors of hepatitis C infection in pregnant women.",[28,93],"HCV Elimination",[95,96,97],"Hepatitis C","HCV elimination","Women of childbearing age","2025-04-23",{"date":100,"type":47},"2025-04-30",{"date":102,"type":21},"2025-04-25",{"date":104,"type":21},"2025-12-31",{"name":106,"class":81},"First Affiliated Hospital Xi'an Jiaotong University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":64,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":5},"100587428","drug-drug-intercations-and-direct-acting-antiviral-agents-against-hcv-100587428","NCT06928259","Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV","Clinical Relevance of Drug-drug Interactions (DDI) With the Currently Used Direct-acting Antiviral Therapy (DAA) Against Hepatitis C Virus (HCV)","Inclusion Criteria:\n\n1. Treatment naive patients who received therapy with GLE\u002FPIB or SOF\u002FVEL between April 1st, 2018, and July 1st, 2023, receiving ≥ 1 comedication or recreational drug.\n2. Attended in a hospital with electronic clinical records allowing access to all clinical visits and prescribed medications, both in all hospitals and in primary care institutions of the corresponding Spanish region during the study period.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from the study:\n\n1. HCV treatment-experienced patients will be excluded.\n2. Patients without any comedication or recreational drug use\n3. Those who have attended private health care",{"count":115,"type":21},728,"Background: Currently used direct-acting antivirals (DAA) share pharmacokinetic pathways with many comedications commonly used in patients with chronic hepatitis C virus (HCV) infection, therefore drug-drug interactions (DDI) might exist. Although extensive (DDI) verification is recommended by most clinical practice guidelines, real-world studies have shown that approximately one-tenth of patients on DAA therapy also take concomitant medication with the potential for significant interactions. Despite the risk of significant DDI when patients are administered DAA and a concomitant medication, to date, there is very little information on whether these interactions translate into changes in the toxicity or efficacy of any involved DAA or comedication in clinical practice. Clarifying this issue is a critical point, as the DDI profile of the currently used DAA is not the same, with SOF\u002FVEL showing a lower risk of significant DDI than GLE\u002FPIB. Thus the objective of this study is to compare the percentage of comedication switch, withdrawal, or dose reduction at treatment initiation and during treatment with GLE\u002FPIB or SOF\u002FVEL.\n\nMethods: The patients will be enrolled from the GEHEP 001\u002FHEPAVIR cohort. \"The HEPAVIR-DAA cohort (NCT02057003)\", includes HIV\u002FHCV-coinfected patients, and \"the GEHEP-MONO cohort (NCT02333292)\", that includes HCV mono-infected individuals, are ongoing prospective multicenter cohorts of patients receiving DAA combinations prescribed in clinical practice, outside clinical trials. Main Study End Point will be the frequency of comedication switch, withdrawal or dose reduction at treatment initiation (index date) and during treatment with GLE\u002FPIB or SOF\u002FVEL.",[28],[34,119,120,121],"SOF\u002FVEL","GLE\u002FPIB","drug-drug interactions","RECRUITING","2025-04-07",{"date":125,"type":47},"2025-04-15",{"date":100,"type":21},{"date":128,"type":21},"2026-03",{"name":130,"class":81},"University of Seville"]